In this article, we will discuss Ramucirumab (15). So, let;s get started.
Infusion-Related Reactions (IRRs)
Prior to the institution of premedication recommendations across clinical trials of Ramucirumab, infusion-related reactions (IRRs) occurred in 6 out of 37 patients (16%), including two severe events. The majority of IRRs across trials occurred during or following a first or second Ramucirumab infusion. Symptoms of IRRs included rigors/tremors, back pain/spasms, chest pain and/or tightness, chills, flushing, dyspnea, wheezing, hypoxia, and paresthesia. In severe cases,
symptoms included bronchospasm, supraventricular tachycardia, and hypotension. Monitor patients during the infusion for signs and symptoms of IRRs in a setting with available resuscitation equipment. Immediately and permanently discontinue Ramucirumab for Grade 3 or 4 IRRs.